IGC - Earnings announcements

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced positive interim results from its ongoing Phase 2 trial for IGC-AD1. The interim data have shown promising results in reducing Alzheimer's agitation, which is a major challenge for patients and their caregivers alike. This development marks a significant step forward in the fight against Alzheimer's and brings hope to millions of people affected by this devastating disease. In January 2024, the Company announced details about its dru

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024). Q3 FY2024 Highlights On October 18, 2023, the European Patent Office ("EPO") issued a patent (#3193862) to the Company titled "Cannabinoid Composition and Method for Treating Pain". The patent introduces a method for treating pain in humans. Utilizing a cream base infused with a unique blend of cannabinoids, including THC and CBD, alongside other compounds, this revolutionary cream, or gel is designed for transdermal absorption. On October 25, 2023, the Divisional Direction of Patents, Mexico, issued a patent (MX/a/2020

IGC-ADI addressing agitation in dementia due to Alzheimer's progresses in Phase 2 Trial Company focuses on advancing the development of an expanded IP portfolio targeting Alzheimer's IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024). Q2 FY2024 Highlights Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000. In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year's six-month period. IGC's revenue was primarily generated from our over-the-cou

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company's 2024 fiscal year. First Fiscal Quarter 2024 Highlights Net revenue increased 161% to approximately $555 thousand in the three months ended June 30, 2023, compared to $212 thousand in the prior year period, driven primarily by the sale of formulations based on the Holief brand natural products targeting women with premenstrual syndrome ("PMS"), period pain, and sleep disorders. Throughout the quarter, IGC Pharma maintained substantial momentum in the development of a Phase 3 manufacturing facility located on the We

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 ("Fiscal 2023"). Full Fiscal Year Highlights and Events Subsequent Thereto On July 7, 2023, the Company announced a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. ("O-Bank" or the "Bank"). This funding will support the working capital needs of the Company, primarily related to Alzheimer's research. On July 6, 2023, the Company announced a $3 million private placement of its common stock. IGC received strategic investments from four investment funds managed by Bradbury Asset Ma

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE:IGC) ("IGC" or the "Company") today reported its third fiscal quarter 2023 financial results. Third Fiscal Quarter 2023 Highlights: The Company expanded the number of sites participating in its Phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer's disease to a total of four – three in the U. S. and one in Canada. The Company is encouraged by the patient enrollment and interest from many of the leading research centers and has decided to increase the number of trial sites to between 10 and 12 from the originally planned

Company To Host Conference Call on Friday, December 2 at 11 a.m. ET India Globalization Capital, Inc. (NYSE:IGC) ("IGC" or the "Company"), announced that it has begun "A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer's Disease". The Company has commenced the Phase 2 study at two U.S. sites with plans to add between three to five additional sites in the United States, Canada, and possibly South America to increase population diversity, promoting both the inclusion of underrepresented populations and helping the Company to better understand the impact of IGC-AD1 on t

India Globalization Capital, Inc. (NYSE:IGC) ("IGC" or the "Company") today reported its second fiscal quarter 2023 financial results. Second Fiscal Quarter 2023 Highlights: IGC-AD1 and TGR-63, both small molecules, have shown potential to suppress or ameliorate a key protein in Alzheimer's cell lines responsible for Aβ plaques, a key hallmark of Alzheimer's disease. The Company currently has two main investigational drug assets in various stages of development: IGC-AD1: The Company's therapeutic candidate is entering Phase 2 trials for treating agitation in dementia from Alzheimer's disease. TGR-63: An enzyme inhibitor shown in preclinical trials to reduce neurotoxicity in Alzheimer

India Globalization Capital, Inc. ("IGC" or the "Company") (NYSE:IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company's 2023 fiscal year. The highlights for the quarter are: The Company has submitted a protocol to the U.S. Food and Drug Administration (FDA) titled "A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer's disease." The protocol is powered at 146 Alzheimer's patients with half receiving placebo and is a superiority, parallel group study. The primary end point is agitation in dementia due

India Globalization Capital, Inc. ("IGC" or the "Company") (NYSE:IGC) announces its financial results for Fiscal Year Ended March 31, 2022. Highlights for Fiscal 2022: IGC completed the first-in-human safety and tolerability trial on its tetrahydrocannabinol (THC) based investigational new drug IGC-AD1. During the trial, the Company discovered positive signals for improving several neuropsychiatric symptoms including agitation in dementia associated with Alzheimer's. Based on these signals, we are initiating a larger efficacy trial to test IGC-AD1 as a symptom modifying agent, specifically on agitation in dementia due to Alzheimer's disease. The Company recently acquired rights to a f

India Globalization Capital, Inc. (NYSE:IGC) announces its financial results for the three months ending December 31, 2021 – quarter three of the Company's 2022 fiscal year. Highlights include: The Company appointed former congressman James Moran to its Board of Directors. During his 24 years in Congress, Moran was recognized as a champion of innovative research and development in areas including healthcare and national security, environmental protection and sustainability, and international trade and fiscal responsibility. The Company completed a Phase 1 clinical trial for IGC-AD1, an investigational new Tetrahydrocannabinol (THC) based drug candidate designed to treat the symptoms o

India Globalization Capital, Inc. (NYSE:IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company's 2022 fiscal year. The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC's tetrahydrocannabinol ("THC") based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer's disease. The primary endpoint of this Phase 1 trial was safety and tolerability. Based on this study and subject to FDA concurrence the cannabis-based investigational drug IGC-AD1 was generally safe and we

India Globalization Capital, Inc. (NYSE:IGC) announces its financial results for the three months ended June 30, 2021. Recent highlights: Patent: On July 20, 2021, the United States Patent and Trademark Office ("USPTO") granted the Company a patent (#11,065,225) for the treatment of Alzheimer's disease entitled "Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's Disease." The original patent application was initiated by the University of South Florida ("USF") and filed on August 1, 2016. IGC holds an exclusive license agreement with USF with respect to the patent and associated research. The patent relates to IGC's proprietary formulation, IGC-AD1, inten

India Globalization Capital, Inc. (NYSE:IGC) announces its financial results for the Fiscal Year Ended March 31, 2021. Revenue was approximately $898 thousand and $4.1 million for Fiscal 2021 and Fiscal 2020, respectively. In Fiscal 2021, the Company's revenues were significantly impacted by the COVID-19 pandemic, which hindered our ability to fully operate either of our two business lines. Revenue in Fiscal 2021 was primarily derived from our Life Sciences segment, which involved sales of products such as alcohol-based hand sanitizers, among others. In Fiscal 2020, our revenue was primarily derived from the infrastructure segment. Due to the ongoing impact of the COVID-19, we currently ha

POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended December 31, 2020, which is the third quarter of its 2021 fiscal year. Revenue in the quarter ended December 31, 2020 and December 31, 2019, was $108 thousand and $573 thousand respectively. The decrease in revenue is from infrastructure and is primarily due to restrictions imposed by the COVID-19 pandemic. The revenue in the quarter ended December 31, 2020 was approximately 15% from the infrastructure segment and approximately 85% from the Life Science segment. In comparison, the revenue in the December 2019 qu